Holen Sie sich die Stockscreener-App
59.55
1.49%
-0.81
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Canada
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vaxcyte stock jumps on new executives, VAX-31 data timeline - Investing.com
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - TipRanks
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Nigeria
Vaxcyte Appoints Chief Medical Officer And Chief Legal Officer Narrows Guidance For Expected Vax-31 Opus-1 Topline Data - TradingView
Vaxcyte appoints two executives, narrows trial timeline By Investing.com - Investing.com Canada
Vaxcyte Inc (PCVX) Updates Phase 3 Trial Timeline, Market Pricin - GuruFocus
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data - Investing News Network
Vaxcyte appoints two executives, narrows trial timeline - Investing.com
Vaxcyte, Inc. Announces Management Changes - marketscreener.com
Vaxcyte COO Jim Wassil sells over $212,000 in company stock By Investing.com - Investing.com South Africa
Vaxcyte COO Jim Wassil sells over $212,000 in company stock - Investing.com
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Vaxcyte Options Spot-On: On September 1st, 90,099 Contracts Were Traded, With 97,138 Open Interest - Moomoo
Vaxcyte (NASDAQ: PCVX) officer lines up new stock sale after recent trades - Stock Titan
Vaxcyte, Inc. (PCVX) Investor Outlook: Biotech Stock With An 82% Potential Upside - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vaxcyte Inc. (PCVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Vaxcyte (PCVX) Pulls Back 2.2% to $59.84, Approaches Key Support at $56.85Volume Gap - vinanet.vn
Vaxcyte to Participate in Upcoming Investor Conferences - The Manila Times
Vaxcyte sets two online fireside chats for September dates - Stock Titan
Vaxcyte (PCVX) Q2 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Investor Response: Shares Finish 1.13% Lower at the CloseProduct Revenue Analysis - vinanet.vn
Vaxcyte (PCVX) Earnings Snapshot: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Session Move - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Vaccine Innovation Leader - DirectorsTalk Interviews
Vaxcyte (PCVX) Earnings Snapshot: Profit Per Share Clears Its Benchmark in the Current Update; After Earnings: Shares Finish 2.09% Higher for the Current SessionEarnings Beat Alert - vinanet.vn
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):